Nautilus Biotechnology, Inc. Investing Cash Flow
Nautilus Biotechnology, Inc. (NAUT) reported Investing Cash Flow of $26.25 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-07-28
- Nautilus Biotechnology, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $12.02M, a 16.94% decline year-over-year.
- Nautilus Biotechnology, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $14.23M, a 27.05% decline year-over-year.
- Nautilus Biotechnology, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $787.00K, a 97.88% decline year-over-year.
- Nautilus Biotechnology, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $452.00K.
- Nautilus Biotechnology, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $35.22M, a 46.83% decline from fiscal 2024.
- Nautilus Biotechnology, Inc. net cash provided by (used in) investing activities for fiscal 2024 was $66.25M.
- Nautilus Biotechnology, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$43.73M.
- Nautilus Biotechnology, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$25.74M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28 | $26.25M 10-Q · filed 2026-07-28 | $27.04M derived: sum of 3 quarters · filed 2026-07-28 | $27.49M derived: sum of 4 quarters · filed 2026-07-28 |
| 2026-03-31 | $14.23M 10-Q · filed 2026-04-28 | $15.02M derived: sum of 2 quarters · filed 2026-04-28 | $15.47M derived: sum of 3 quarters · filed 2026-04-28 | $29.95M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-12-31 | $787.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.24M derived: sum of 2 quarters · filed 2026-02-26 | $15.71M derived: sum of 3 quarters · filed 2026-07-28 | $35.22M 10-K · filed 2026-02-26 |
| 2025-09-30 | $452.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $14.93M derived: sum of 2 quarters · filed 2026-07-28 | $34.44M 10-Q · filed 2025-10-28 | $71.54M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-06-30 | $14.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28 | $33.98M 10-Q · filed 2026-07-28 | $71.09M derived: sum of 3 quarters · filed 2026-07-28 | $63.59M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-03-31 | $19.51M 10-Q · filed 2026-04-28 | $56.62M derived: sum of 2 quarters · filed 2026-04-28 | $49.11M derived: sum of 3 quarters · filed 2026-04-28 | $63.41M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $37.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $29.60M derived: sum of 2 quarters · filed 2026-02-26 | $43.90M derived: sum of 3 quarters · filed 2026-02-26 | $66.25M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$7.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $6.79M derived: sum of 2 quarters · filed 2025-10-28 | $29.14M 10-Q · filed 2025-10-28 | -$11.92M derived: sum of 4 quarters · filed 2025-10-28 |
| 2024-06-30 | $14.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $36.65M 10-Q · filed 2025-07-31 | -$4.41M derived: sum of 3 quarters · filed 2025-07-31 | $8.66M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | $22.35M 10-Q · filed 2025-04-29 | -$18.71M derived: sum of 2 quarters · filed 2025-04-29 | -$5.63M derived: sum of 3 quarters · filed 2025-04-29 | -$7.89M derived: sum of 4 quarters · filed 2025-04-29 |
| 2023-12-31 | -$41.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$27.98M derived: sum of 2 quarters · filed 2025-02-27 | -$30.24M derived: sum of 3 quarters · filed 2025-02-27 | -$43.73M 10-K · filed 2025-02-27 |
| 2023-09-30 | $13.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $10.82M derived: sum of 2 quarters · filed 2024-10-29 | -$2.67M 10-Q · filed 2024-10-29 | -$66.73M derived: sum of 4 quarters · filed 2024-10-29 |
| 2023-06-30 | -$2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | -$15.75M 10-Q · filed 2024-07-30 | -$79.81M derived: sum of 3 quarters · filed 2024-07-30 | -$91.75M derived: sum of 4 quarters · filed 2024-07-30 |
| 2023-03-31 | -$13.49M 10-Q · filed 2024-04-30 | -$77.55M derived: sum of 2 quarters · filed 2024-04-30 | -$89.49M derived: sum of 3 quarters · filed 2024-04-30 | -$54.42M derived: sum of 4 quarters · filed 2024-04-30 |
| 2022-12-31 | -$64.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$76.00M derived: sum of 2 quarters · filed 2024-02-28 | -$40.92M derived: sum of 3 quarters · filed 2024-02-28 | -$25.74M 10-K · filed 2024-02-28 |
| 2022-09-30 | -$11.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $23.13M derived: sum of 2 quarters · filed 2023-10-31 | $38.31M 10-Q · filed 2023-10-31 | $44.38M derived: sum of 4 quarters · filed 2023-10-31 |
| 2022-06-30 | $35.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $50.26M 10-Q · filed 2023-08-02 | $56.32M derived: sum of 3 quarters · filed 2023-08-02 | -$27.66M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | $15.18M 10-Q · filed 2023-05-02 | $21.25M derived: sum of 2 quarters · filed 2023-05-02 | -$62.73M derived: sum of 3 quarters · filed 2023-05-02 | -$147.30M derived: sum of 4 quarters · filed 2023-05-02 |
| 2021-12-31 | $6.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$77.92M derived: sum of 2 quarters · filed 2023-02-23 | -$162.48M derived: sum of 3 quarters · filed 2023-02-23 | -$138.96M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$83.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | -$168.55M derived: sum of 2 quarters · filed 2022-11-01 | -$145.03M 10-Q · filed 2022-11-01 | -$145.03M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | -$84.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | -$61.05M 10-Q · filed 2022-08-02 | -$61.05M derived: sum of 3 quarters · filed 2022-08-02 | -$77.34M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $23.52M 10-Q · filed 2022-05-03 | $23.52M derived: sum of 2 quarters · filed 2022-05-03 | $7.23M derived: sum of 3 quarters · filed 2022-05-03 | |
| 2020-12-31 | $0.00 derived: 10-K 9 month − 10-Q 6 month · filed 2021-03-30 | -$16.29M derived: sum of 2 quarters · filed 2021-11-02 | -$149.50M 10-K · filed 2021-03-30 | -$25.28M 10-K · filed 2022-02-24 |
| 2020-09-30 | -$16.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$149.50M 10-Q · filed 2020-11-13 | -$53.98M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | -$37.69M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |